The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
Open accessAbstract
Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data from a custom high-density array of 46,939 PrCa cases and 27,910 controls of European ancestry with previously genotyped data of 32,255 PrCa cases and 33,202 controls of European ancestry. Our analysis identified 62 novel loci associated (P < 5.0 × 10-8) with PrCa and one locus significantly associated with early-onset PrCa (≤55 years). Our findings include missense variants rs1800057 (odds ratio (OR) = 1.16; P = 8.2 × 10-9; G>C, p.Pro1054Arg) in ATM and rs2066827 (OR = 1.06; P = 2.3 × 10-9; T>G, p.Val109Gly) in CDKN1B. The combination of all loci captured 28.4% of the PrCa familial relative risk, and a polygenic risk score conferred an elevated PrCa risk for men in the ninetieth to ninety-ninth percentiles (relative risk = 2.69; 95% confidence interval (CI): 2.55-2.82) and first percentile (relative risk = 5.71; 95% CI: 5.04-6.48) risk stratum compared with the population average. These findings improve risk prediction, enhance fine-mapping, and provide insight into the underlying biology of PrCa 1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, polygenic risk scores alone already predict breast cancer, prostate cancer, and type 1 diabetes risk in European descent patients more accurately than current clinical models2–4.”
From Clinical use of current polygenic risk scores may exacerbate health disparities (2019) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Gene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,724
METAL: fast and efficient meta-analysis of genomewide association scans
Willer, C. J., Li, Y., & Abecasis, G. R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq340 · Cited by 5,205
Howie, B. N., Donnelly, P., & Marchini, J. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000529 · Cited by 3,928
PANTHER: A Library of Protein Families and Subfamilies Indexed by FunctionPreprint
Thomas, P. D., Campbell, M. J., Kejariwal, A., Mi, H., Karlak, B., Daverman, R., Diemer, K., Muruganujan, A., & Narechania, A. (2003) · Genome Research · doi:10.1101/gr.772403 · Cited by 2,978
Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation
Merico, D., Isserlin, R., Stueker, O., Emili, A., & Bader, G. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013984 · Cited by 2,235
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Cited by
Sorted by citations
Items 201–300 of 918
Transcriptomic and Genetic Associations between Alzheimer’s Disease, Parkinson’s Disease, and Cancer
Forés-Martos, J., Boullosa, C., Domínguez, D. R., Sánchez-Valle, J., Suay‐García, B., Climent, J., Falcó, A., Valencia, A., Puig‐Butillé, J. A., Puig, S., et al. (2021) · Cancers · doi:10.3390/cancers13122990 · Cited by 36
“PRCA 1 GWAS catalog [66] 140,254 (79,148/61,106) 1,206,082 1.”
Wang, M., Jian, Z., Chi, Y., Jin, X., Li, H., & Wang, K. (2021) · Nutrients · doi:10.3390/nu13072317 · Cited by 34
Wu, L., Shu, X., Bao, J., Guo, X., Kote‐Jarai, Z., Haiman, C. A., Eeles, R. A., & Zheng, W. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3997 · Cited by 33
“We used the data from 79,194 cases and 61,112 controls of European descent included in GWAS consortia PRACTICAL, CRUK, CAPS, BPC3 and PEGASUS, as described previously(23).”
BackgroundMethodResultInfluentialSelf-citationModel-based assessment of replicability for genome-wide association meta-analysis
McGuire, D., Jiang, Y., Liu, M., Weissenkampen, J. D., Eckert, S., Yang, L., Chen, F., Liu, M., Jiang, Y., Wedow, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21226-z · Cited by 30
Self-citationUnravelling the complex causal effects of substance use behaviours on common diseases
Xue, A., Zhu, Z., Wang, H., Jiang, L., Visscher, P. M., Zeng, J., & Yang, J. (2024) · Communications Medicine · doi:10.1038/s43856-024-00473-3 · Cited by 32
Khoei, N. S., Carreras‐Torres, R., Murphy, N., Gunter, M. J., Brennan, P., Smith-Byrne, K., Mariosa, D., McKay, J., O’Mara, T. A., Jarrett, R. F., et al. (2021) · Cells · doi:10.3390/cells10020394 · Cited by 34
Genetically proxied morning chronotype was associated with a reduced risk of prostate cancer
Sun, X., Ye, D., Jiang, M., Qian, Y., & Mao, Y. (2021) · SLEEP · doi:10.1093/sleep/zsab104 · Cited by 31
Ren, Z., Wei, Y., & Candès, E. J. (2021) · Journal of the American Statistical Association · doi:10.1080/01621459.2021.1962720 · Cited by 34
“We take the meta-analysis conducted by Schumacher et al. (2018) as the early-stage study, and apply derandomized knockoffs on a dataset from the U.K. Biobank for a confirmatory analysis.”
MethodResultLindström, S., Wang, L., Feng, H., Majumdar, A., Huo, S., MacDonald, J. W., Harrison, T. A., Turman, C., Chen, H., Mancuso, N., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad043 · Cited by 33
Self-citationGenomic landscape of cancer in racially and ethnically diverse populations
Thomas, C. E., & Peters, U. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-024-00796-w · Cited by 32
“…number of companies are offering PRSs directly to consumers and healthcare providers, we urgently need to evaluate the clinical value of PRS for risk-stratified screening 84 , given that many of the scores embedded in such testing were primarily derived in European ancestry populations 85–87 .”
Liu, D., Zhu, J., Zhou, D., Nikas, E. G., Mitanis, N. T., Sun, Y., Wu, C., Mancuso, N., Cox, N. J., Wang, L., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33808 · Cited by 33
“The detailed information of this meta-analysis has been described elsewhere.(26) Briefly, a total of 46 939 cases and 27 910 controls were genotyped using OncoArray including 570 000 SNPs (http://epi.”
MethodSelf-citationLin, H., & Park, J. Y. (2023) · Springer eBooks · doi:10.1007/978-3-031-50977-3_2 · Cited by 33
Self-citationSrinivasan, S., Stephens, C. R., Wilson, E., Panchadsaram, J., deVoss, K., Koistinen, H. K., Stenman, U., Brook, M. N., Buckle, A. M., Klein, R. J., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.295790 · Cited by 30
Self-citationJung, S. Y., Papp, J. C., Sobel, E. M., Yu, H., & Zhang, Z. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3688 · Cited by 30
“The second quality control process included SNPs with R̂2 0:6 imputation quality (21) and excluded women with a kinship estimate with R̂2 0:25: At baseline, fasting blood samples from each participant were collected by trained phlebotomists.”
MethodShi, Z., Yu, H., Wu, Y., Lin, X., Bao, Q., Jia, H., Perschon, C. R., Duggan, D. J., Helfand, B. T., Zheng, S. L., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2143 · Cited by 32
Self-citationLarsson, S. C., Carter, P., Vithayathil, M. K., Mason, A. M., Michaëlsson, K., Baron, J. A., & Burgess, S. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.11.004 · Cited by 30
“…Consortium (n ¼ 27,209) [14], Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome consortium (n ¼ 140,254) [15], Breast Cancer Association Consortium (n ¼ 228,951) [16], Ovarian Cancer Association Consortium (n ¼ 66,450) [17] and BioBank Japan (n ¼ 212,453)…”
Fonseca, L., Sena, B. F., Crossley, N. A., López‐Jaramillo, C., Koenen, K. C., Freimer, N. B., Bressan, R. A., Belangero, S. I., Santoro, M. L., & Gadelha, A. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-1240 · Cited by 30
Spear, M. L., Diaz-Papkovich, A., Ziv, E., Yracheta, J., Gravel, S., Torgerson, D. G., & Hernandez, R. D. (2020) · eLife · doi:10.7554/elife.56029 · Cited by 31
Effect of Basal Metabolic Rate on Cancer: A Mendelian Randomization Study
Ng, J. C. M., & Schooling, C. M. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.735541 · Cited by 29
Polygenic risk scores: the future of cancer risk prediction, screening, and precision prevention
Wang, Y., Zhu, M., Ma, H., & Shen, H. (2021) · Medical Review · doi:10.1515/mr-2021-0025 · Cited by 32
Hayes, B., Robinson, T., Kar, S., Ruth, K. S., Tsilidis, K. K., Frayling, T. M., Murray, A., Martin, R. M., Lawlor, D. A., & Richmond, R. C. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1009887 · Cited by 28
“For breast and prostate cancer outcomes, genome-wide association studies (GWAS) summary data were obtained from the Breast Cancer Association Consortium (BCAC) [32, 37]; and the Elucidating Loci Involved in Prostate Cancer (ELLIPSE) and Prostate Cancer Association Group to Investigate Cancer Associated Alterations in…”
BackgroundSelf-citationInvestigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers
Sugier, P., Lucotte, E. A., Domenighetti, C., Law, M. H., Iles, M. M., Brown, K. M., Amos, C. I., McKay, J., Hung, R. J., Karimi, M., et al. (2023) · Movement Disorders · doi:10.1002/mds.29337 · Cited by 30
“PRSs for each cancer were aligned in Courage-PD using independent genome-wide significant SNPs and corresponding weights for PRS previously published in the largest GWAS to date on this cancer.(27,28,32-36) The lists of SNPs and corresponding weights used for cancer PRSs are described in Table S3A–F.”
Self-citationGene-based burden tests of rare germline variants identify six cancer susceptibility genes
Ivarsdottir, E. V., Guðmundsson, J., Tragante, V., Sveinbjörnsson, G., Kristmundsdóttir, S., Stacey, S., Halldorsson, G. H., Magnusson, M. I., Oddsson, Á., Walters, G. B., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01966-6 · Cited by 29
“A common variant, located in a transcription factor binding site, downstream of BIK , has been reported to associate with prostate cancer 39 (rs5759167, MAF = 49.9% in the UK Biobank dataset), and a noncoding rare variant downstream of BIK was recently reported to associate with prostate cancer in…”
InfluentialSelf-citationSingle-Nucleotide Polymorphism–Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis
Na, R., Labbate, C. V., Yu, H., Shi, Z., Fantus, R. J., Wang, C., Andriole, G. L., Isaacs, W. B., Zheng, S. L., Helfand, B. T., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.18145 · Cited by 28
Self-citationDNA methylation and cis-regulation of gene expression by prostate cancer risk SNPs
Dai, J. Y., Wang, X., Wang, B., Sun, W., Jordahl, K. M., Kolb, S., Nyame, Y. A., Wright, J. L., Ostrander, E. A., Feng, Z., et al. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008667 · Cited by 28
“The most recent and the largest GWAS to date assembled 79,194 cases and 61,112 controls of European ancestry from 59 studies for genotyping on a custom high-density genotyping array (the OncoArray), identified 62 novel loci associated with overall PrCa risk [29].”
BackgroundSelf-citationChen, J., Li, R., Deng, T., Lin, Z., Li, H., Yang, Y., Su, Q., Wang, J., Yang, Y., Wang, J., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.899137 · Cited by 29
“(36), including 79,148 patients and 61,106 controls; the summary statistics for bladder cancer included 1,279 patients and 372,016 controls; summary statistics for brain cancer included 606 patients and 372,016 controls; and summary statistics for cervical cancer included 563 patients and 198,523 controls.”
BackgroundThe Etiology of Prostate Cancer
Ng, K. L. (2021) · Exon Publications eBooks · doi:10.36255/exonpublications.prostatecancer.etiology.2021 · Cited by 38
Active DHEA uptake in the prostate gland correlates with aggressive prostate cancer
Zhang, X., Wang, Z., Huang, S., He, D., Yan, W., Zhuang, Q., Wang, Z., Wang, C., Tan, Q., Liu, Z., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci171199 · Cited by 28
“Individuals with high scores of the DHEA GWAS signature also showed higher UKBB-PRS and PRACTICAL-PRS, suggesting a shared genet-ic component of prostatic DHEA utilization and prostate cancer risk (Figure 3B).”
BackgroundMethodInfluentialMoksnes, M. R., Hansen, A. F., Wolford, B. N., Thomas, L. F., Rasheed, H., Simić, A., Bhatta, L., Brantsæter, A. L., Surakka, I. L., Zhou, W., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06101-z · Cited by 31
Dee, E. C., Todd, R., Ng, K., Aidoo-Micah, G., Amen, T. B., Moon, Z., Vince, R., Muralidhar, V., Mutsvangwa, K., Funston, G., et al. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00948-x · Cited by 28
Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer
Shackleton, E. G., Ali, H. Y., Khan, M. A., Pockley, A. G., & McArdle, S. (2021) · Cancers · doi:10.3390/cancers13051145 · Cited by 29
“4% of familial risk, most of which occur commonly but are of low penetrance [10].”
BackgroundCausal Associations between Serum Urea and Cancer: A Mendelian Randomization Study
Sun, Y., Li, J., Qu, Z., Yang, Z. R., Jia, X., Lin, Y., He, Q., Zhang, L., & Luo, Y. (2021) · Genes · doi:10.3390/genes12040498 · Cited by 28
“Summary genetic data for prostate cancer were obtained from GWAS’s publicly metaanalyses [29] (Table 1).”
MethodChang, E. K., Gadzinski, A. J., & Nyame, Y. A. (2021) · Asian journal of urology · doi:10.1016/j.ajur.2021.06.003 · Cited by 28
“[78] identified 63 new PCa susceptibility loci.”
BackgroundDesai, T. A., Hedman, Å. K., Dimitriou, M., Koprulu, M., Figiel, S., Yin, W., Johansson, M., Watts, E. L., Atkins, J. R., Sokolov, A. V., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105168 · Cited by 31
Self-citationBen, S., Ding, Z., Xin, J., Li, F., Cheng, Y., Chen, S., Fan, L., Zhang, Q., Li, S., Du, M., et al. (2024) · Advanced Science · doi:10.1002/advs.202402954 · Cited by 26
Limited overlap between genetic effects on disease susceptibility and disease survival
Yang, Z., Pajuste, F., Zguro, K., Cheng, Y., Kurant, D. E., Eoli, A., Wanner, J., Jermy, B. S., Rämö, J. T., FinnGen, et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02342-8 · Cited by 27
Genetic factors associated with prostate cancer conversion from active surveillance to treatment
Jiang, Y., Meyers, T. J., Emeka, A. A., Cooley, L. F., Cooper, P. R., Lancki, N., Helenowski, I., Kachuri, L., Lin, D. W., Stanford, J. L., et al. (2021) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2021.100070 · Cited by 27
Self-citationGiannareas, N., Zhang, Q., Yang, X., Na, R., Tian, Y., Yang, Y., Ruan, X., Huang, D., Yang, X., Wang, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34994-z · Cited by 28
Indoleamine 2,3-dioxygenase and ischemic heart disease: a Mendelian Randomization study
Li, M., Kwok, M. K., Fong, S. S. M., & Schooling, C. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-44819-7 · Cited by 29
Xu, H., Wang, X., Xu, X., Liu, L., Zhang, Y., Yan, X., Zhang, Y., Dang, K., & Li, Y. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.10.019 · Cited by 26
xQTLbiolinks: a comprehensive and scalable tool for integrative analysis of molecular QTLs
Ding, R., Zou, X., Qin, Y., Gong, L., Chen, H., Ma, X., Guang, S., Chen, Y., Wang, G., & Li, L. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad440 · Cited by 25
“Here,we applied xQTLbiolinks to integrate the PCa GWAS dataset [28] with xQTLs data from GTEx prostate tissue and aimed to identify putative causal variants and susceptibility genes associated with PCa.”
MethodSelf-citationLi, R., Peng, L., Deng, D., Li, G., & Wu, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1354528 · Cited by 26
“(22).”
Zheng, J., Lu, J., Qi, J., Yang, Q., Zhao, H., Liu, H., Chen, Z., Huang, L., Ye, Y., Xu, M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101688 · Cited by 29
“The summary genetic association data from a case-control genome-wide association study (GWAS) of prostate cancer in the PRACTICAL and GAME-ON/ELLIPSE Consortium 17,18 were used ( n = 140,254 men from the general population; Table S5; more details in the STAR Methods, the PRACTICAL and GAME-ON/ELLIPSE Consortium).”
Self-citationCancer risks in patients with vitiligo: a Mendelian randomization study
Wen, Y., Wu, X., Peng, H., Li, C., Jiang, Y., Liang, H., Zhong, R., Liu, J., He, J., & Liang, W. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03245-3 · Cited by 26
Lin, Y., Yang, Z. R., Li, J., Sun, Y., Zhang, X., Qu, Z., Luo, Y., & Zhang, L. (2022) · BMC Genomics · doi:10.1186/s12864-022-08442-7 · Cited by 28
“Here, exploiting genetically instrumented glutamate and aspartate from GWAS [21] and large case–control studies of prostate and breast cancers with extensive genotyping [22, 23], an MR study was performed to estimate the causal effects of serum glutamate and aspartate levels and the development of prostate and breast…”
MethodInherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer
Rantapero, T., Wahlfors, T., Kähler, A. K., Hultman, C. M., Lindberg, J., Tammela, T. L. J., Nykter, M., Schleutker, J., & Wiklund, F. E. (2020) · Genes · doi:10.3390/genes11030314 · Cited by 28
“Genome-wide association studies (GWAS) have thus far confirmed ~170 susceptibility loci that account for over 30% of the familial relative risk [3].”
BackgroundSelf-citationWan, B., Lu, L., & Lv, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286219 · Cited by 26
Transcriptional mediators of treatment resistance in lethal prostate cancerPreprint
He, M. X., Cuoco, M. S., Crowdis, J. P., Bosma-Moody, A., Zhang, Z., Bi, K., Kanodia, A., Su, M.-J., Rodman, C., DelloStritto, L. K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.19.998450 · Cited by 25
Self-citationHeterogeneous genetic architectures of prostate cancer susceptibility in sub-Saharan Africa
Janivara, R., Chen, W. C., Hazra, U., Baichoo, S., Agalliu, I., Kachambwa, P., Simonti, C. N., Brown, L., Tambe, S. P., Kim, M. S., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01931-3 · Cited by 26
Self-citationPeng, D., Liu, X., Sheng, Y.-H., Li, S.-Q., Zhang, D., Chen, B., Yu, P., Li, Z., Li, S., & Xu, R.-B. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.137619 · Cited by 25
Zhou, H., & Zhu, X. (2018) · Cancer Management and Research · doi:10.2147/cmar.s177551 · Cited by 24
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer
collaborators, U., Karunamuni, R. A., BioResource), A. B. (. P. C., Canary PASS Investigators, Huynh‐Le, M., Fan, C. C., Thompson, W. K., Eeles, R. A., Kote‐Jarai, Z., Muir, K. R., et al. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-00311-2 · Cited by 24
Self-citationThe Impact of Homocysteine on the Risk of Hormone-Related Cancers: A Mendelian Randomization Study
He, Q., Yang, Z. R., Sun, Y., Qu, Z., Jia, X., Li, J., Lin, Y., & Luo, Y. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.645371 · Cited by 24
“For PrCa, we extracted summary-level data from the GWAS meta-analysis of Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome (PRATICAL) consortium comprising of 79,148 cases and 61,106 disease-free controls of European ancestry [PrCa–GWAS] (40).”
MethodInherited Mutations in Chinese Men With Prostate Cancer
Zhu, Y., Yu, W., Zeng, H., Li, Y., Ng, C., Zhou, F., He, C., Sun, G., Ni, Y., Chiu, P. K., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7010 · Cited by 24
Blood pressure and risk of cancer: a Mendelian randomization study
Chan, I. I., Kwok, M. K., & Schooling, C. M. (2021) · BMC Cancer · doi:10.1186/s12885-021-09067-x · Cited by 24
“, breast (133384 cases and 113789 non-cases) [37], prostate (79194 cases and 61112 non-cases) [38] and lung (10246 cases and 38295 non-cases) [39], which have larger number of cases and do not overlap with the UK Biobank or GERA.”
BackgroundApplying Mendelian randomization to appraise causality in relationships between nutrition and cancer
Wade, K. H., Yarmolinsky, J., Giovannucci, E. L., Lewis, S. J., Millwood, I. Y., Munafo, M. R., Meddens, S. F. W., Burrows, K., Bell, J. A., Davies, N. M., et al. (2022) · Cancer Causes & Control · doi:10.1007/s10552-022-01562-1 · Cited by 25
Self-citationLumsden, A. L., Mulugeta, A., & Hyppönen, E. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.11.006 · Cited by 26
Inflammatory bowel disease and prostate cancer risk: a two-sample Mendelian randomization analysis
Cheng, W., Liao, Y., Mou, R., Xiao, X. M., & Jia, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1157313 · Cited by 25
Brandão, A., Paulo, P., Maia, S., Pinheiro, M., Peixoto, A., Cardoso, M., Silva, M. P., Santos, C., Eeles, R. A., Kote‐Jarai, Z., et al. (2020) · Cancers · doi:10.3390/cancers12113254 · Cited by 22
“The quality control of the high-density SNP data from chromosome 22 was performed as previously described [4].”
MethodSelf-citationProstate Cancer Predisposition
Bhanji, Y., Isaacs, W. B., Xu, J., & Cooney, K. A. (2021) · Urologic Clinics of North America · doi:10.1016/j.ucl.2021.03.001 · Cited by 31
Self-citationA Systematic Framework for Assessing the Clinical Impact of Polygenic Risk ScoresPreprint
Kulm, S., Marderstein, A. R., Mezey, J. G., & Elemento, O. (2020) · SSRN Electronic Journal · doi:10.1101/2020.04.06.20055574 · Cited by 25
Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk
Bancroft, E. K., Raghallaigh, H. N., Page, E. C., & Eeles, R. A. (2021) · Current Genetic Medicine Reports · doi:10.1007/s40142-021-00202-5 · Cited by 22
Self-citationKneppers, J., Severson, T., Siefert, J. C., Schol, P. J., Joosten, S. E. P., Yu, I. P. L., Huang, C.-C. F., Morova, T., Altıntaş, U. B., Giambartolomei, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35135-2 · Cited by 22
Kobayashi, T., Hachiya, T., Ikehata, Y., & Horie, S. (2023) · Frontiers in Aging · doi:10.3389/fragi.2023.1176451 · Cited by 23
Genome-Based Classification and Therapy of Prostate Cancer
Angeles, A. K., Bauer, S., Ratz, L., Klauck, S. M., & Sültmann, H. (2018) · Diagnostics · doi:10.3390/diagnostics8030062 · Cited by 23
“More recently, a large-scale meta-analysis of genotypes from more than 140,000 men has identified 63 novel PCa susceptibility loci [10].”
BackgroundCommon Susceptibility Loci for Male Breast Cancer
Maguire, S. L., Perraki, E., Tomczyk, K., Jones, M. E., Fletcher, O., Pugh, M., Winter, T., Thompson, K., Cooke, R., Trainer, A. H., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa101 · Cited by 22
“To assess cross-cancer genetic correlations with other hormonally driven cancers, we used summary statistics from 79 148 prostate cancer cases and 61 106 controls in the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome Consortium (PRACTICAL) (18) and 22 406 invasive epitheli…”
MethodSelf-citationEmami, N. C., Cavazos, T. B., Rashkin, S. R., Cario, C. L., Graff, R. E., Tai, C. G.-L., Mefford, J., Kachuri, L., Wan, E., Wong, S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2635 · Cited by 20
“In contrast, genome-wide association studies (GWAS) of more common variants have identified nearly 200 independent genetic variants associated with prostate cancer (6).”
MethodRen, S., Li, J., Dorado, J., Sierra, A., González‐Díaz, H., Duardo-Sánchez, A., & Shen, B. (2023) · Health Information Science and Systems · doi:10.1007/s13755-023-00264-5 · Cited by 22
“At the same time, with the proliferation of large-scale fine-mapping studies [79], nearly 270 known PCa gene loci have been identified to date, including more than 400 SNPs with significant significance [80–82].”
The landscape of N6-methyladenosine in localized primary prostate cancer
Xu, X., Zhu, H. H., Hugh-White, R., Livingstone, J. M., Eng, S. E., Zeltser, N., Wang, Y., Pajdzik, K., Chen, S., Houlahan, K. E., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02128-y · Cited by 22
“Next, to understand potential epitranscriptomic alterations characteristic of prostate cancer incidence, we evaluated the association of m 6 A peaks with two polygenic risk scores (PRSs) for incidence 49,50 and one for hazard (PHS290) 51 (Fig.”
Self-citationKe, C., Chen, L., Yu, C., Cheng, W., Huang, C., Lin, V. C.-H., Lu, T., Huang, S., & Bao, B. (2020) · Cancers · doi:10.3390/cancers12051346 · Cited by 21
“Further functional studies indicate that these risk loci are often located near genes, and regulate genes involved in carcinogenesis, including cell metabolism (JAZF1 and HNF1B) and DNA repair or cell cycle machinery (MYC, TERT, ATM, and CDKN1B) [4].”
BackgroundLarge-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals
Chen, H., Majumdar, A., Wang, L., Kar, S., Brown, K. M., Feng, H., Turman, C., Dennis, J., Easton, D. F., Michailidou, K., et al. (2021) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2021.100041 · Cited by 21
Self-citationCancers and COVID-19 Risk: A Mendelian Randomization Study
Li, Z., Wei, Y., Zhu, G., Wang, M., & Zhang, L. (2022) · Cancers · doi:10.3390/cancers14092086 · Cited by 22
“The summary statistics of the GWASs for cancers were obtained from the UK biobank [25], International Lung Cancer Consortium (ILCCO) [26], Breast Cancer Association Consortium (BCAC) [27], Ovarian Cancer Association Consortium (OCAC) [28], Endometrial Cancer Association Consortium (ECAC) [29], Prostate Cancer Associat…”
MethodGenetic and modifiable risk factors combine multiplicatively in common disease
Pang, S., Yengo, L., Nelson, C. P., Bourier, F. J., Zeng, L., Li, L., Kessler, T., Erdmann, J., Mägi, R., Läll, K., et al. (2022) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02081-4 · Cited by 21
“For both diseases, the 134 published [2, 3] genome-wide significant risk variants were normally distributed (Fig.”
BackgroundMechanistic insights into genetic susceptibility to prostate cancer
Tian, P. W., Zhong, M., & Wei, G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.025 · Cited by 22
Circulating phosphorus concentration and risk of prostate cancer: a Mendelian randomization study
Lv, L., Ye, D., Chen, J., Qian, Y., Fu, A., Song, J., Yang, H., Liu, B., Sun, X., Du, L., et al. (2021) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqab342 · Cited by 20
Wang, M., Jian, Z., Gao, X., Chi, Y., Jin, X., Li, H., & Wang, K. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.742952 · Cited by 20
“GWAS Data Sources for 14 Urological and Reproductive Outcomes We extracted summary statistics for prostate cancer (79,148 cases and 61,106 controls) from the Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome (PRACTICAL) Consortium (23).”
MethodXu, J., Resurreccion, W. K., Shi, Z., Wei, J., Wang, C., Zheng, S. L., Hulick, P. J., Ross, A. E., Pavlovich, C. P., Helfand, B. T., et al. (2022) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00458-6 · Cited by 20
“Several characteristics of these risk-associated SNPs are summarized in Box 1 (Supplementary file 1) and discussed below: They are consistently replicated in large studies [23, 25, 52].”
BackgroundSelf-citationvon Berg, J., ten Dam, M., van der Laan, S. W., & de Ridder, J. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac228 · Cited by 21
Genetic risk, metabolic syndrome, and gastrointestinal cancer risk: A prospective cohort study
Liu, Y., Yan, C., Yin, S., Wang, T., Zhu, M., Liu, L., & Jin, G. (2022) · Cancer Medicine · doi:10.1002/cam4.4923 · Cited by 20
Plym, A., Zhang, Y., Stopsack, K. H., Jee, Y. H., Wiklund, F. E., Kibel, A. S., Kraft, P. L., Giovannucci, E. L., Penney, K. L., & Mucci, L. A. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1723 · Cited by 21
“Of these men, 10,917 have been genotyped as a part of multiple nested case – control studies as described previously (11), including a prostate cancer case – control study of 2,000 cases and controls (12).”
Self-citationKeeney, E., Sanghera, S., Martin, R. M., Gulati, R., Wiklund, F. E., Walsh, E. I., Donovan, J., Hamdy, F. C., Neal, D. E., Lane, J. A., et al. (2022) · PharmacoEconomics · doi:10.1007/s40273-022-01191-1 · Cited by 20
“68 on the natural logarithm scale, such that the frailty has a mean of 1 [13, 36, 37].”
BackgroundSelf-citationPrognostic Value of CD1B in Localised Prostate Cancer
Lee, C., Chen, L., Yu, C., Lin, W., Lin, V. C.-H., Huang, C., Lu, T., Huang, S., & Bao, B. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16234723 · Cited by 20
“There are now more than 100 prostate cancer susceptibility loci that have been identified by genome-wide association studies and have been thought to explain 30% of the disease heritability [3].”
BackgroundWei, J., Shi, Z., Na, R., Resurreccion, W. K., Wang, C., Duggan, D. J., Zheng, S. L., Hulick, P. J., Helfand, B. T., & Xu, J. (2020) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2020-107286 · Cited by 20
Self-citationGermline Genetics of Prostate Cancer: Time to Incorporate Genetics into Early Detection Tools
Fantus, R. J., & Helfand, B. T. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.286658 · Cited by 18
Causal roles of circulating adiponectin in osteoporosis and cancers
He, B., Zhao, J., Zhang, M., Yin, L., Quan, Z., Ou, Y., & Huang, W. (2021) · Bone · doi:10.1016/j.bone.2021.116266 · Cited by 20
Precision intervention for prostate cancer: Re-evaluating who is at risk
Papachristodoulou, A., & Abate-Shen, C. T. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215709 · Cited by 20
Atopic dermatitis and risk of 14 site‐specific cancers: A Mendelian randomization study
Liu, Q., Chen, L., Wang, Y., Wang, X., Lewis, S. J., & Wang, J. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19380 · Cited by 19
Using clinical and genetic risk factors for risk prediction of 8 cancers in the UK Biobank
Hu, J., Ye, Y., Zhou, G., & Zhao, H. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae008 · Cited by 19
Chen, H., Wang, Z., Gong, L., Wang, Q., Chen, W., Wang, J., Ma, X., Ding, R., Li, X., Zou, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46064-7 · Cited by 19
Liss, M. A., Leach, R. J., Sanda, M. G., & Semmes, O. J. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-1104 · Cited by 18
“This information will be useful for evaluating newly described polygenetic risk score, such as those developed by the PRACTICAL consortium (67, 68), and can also be used for evaluating men with DNA damage repair gene mutations such asBRCA2 andATM, whichhave been shown to be associatedwith grade reclassification in men…”
MethodInteractions ofPVT1andCASC11on Prostate Cancer Risk in African Americans
Lin, H., Callan, C. Y., Fang, Z., Tung, H.-Y., & Park, J. Y. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-1092 · Cited by 19
“org Cancer Epidemiol Biomarkers Prev; 28(6) June 2019 1069”
BackgroundInfluentialSelf-citationJones, G., Trajanoska, K., Santanasto, A. J., Stringa, N., Kuo, C., Atkins, J. L., Lewis, J. R., Duong, T., Hong, S., Biggs, M. L., et al. (2020) · medRxiv · doi:10.1101/2020.05.14.20100354 · Cited by 19
A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer
Srinivasan, S., Kryza, T., Bock, N., Tse, B. W.-C., Sokolowski, K. A., Panchadsaram, J., Fernando, A., Moya, L., Stephens, C. R., Dong, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52472-6 · Cited by 18
“All regression analyses were performed using SPSS, R and Stata 14 16 .”
InfluentialSelf-citationOptimization of multi-ancestry polygenic risk score disease prediction models
Lerga-Jaso, J., Terpolovsky, A., Novković, B., Osama, A., Manson, C., Bohn, S., Marino, A. D., Kunitomi, M., & Yazdi, P. G. (2025) · Scientific Reports · doi:10.1038/s41598-025-02903-1 · Cited by 21
An appraisal of genetic testing for prostate cancer susceptibility
Finch, A., Clark, R. K., Vesprini, D., Lorentz, J., Kim, R. H., Thain, E., Fleshner, N. E., Akbari, M. R., Cybulski, C., & Narod, S. A. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00282-8 · Cited by 18
Self-citationTian, Y., Dong, D., Wang, Z., Wu, L., Park, J. Y., Wei, G., & Wang, L. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.07.003 · Cited by 18
Self-citationPeripheral transcriptomic biomarkers for early detection of sporadic Alzheimer disease?
Hadar, A., & Gurwitz, D. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.4/dgurwitz · Cited by 18
Rare germline genetic variants and risk of aggressive prostate cancer
Nguyen‐Dumont, T., MacInnis, R. J., Steen, J. A., Theys, D., Tsimiklis, H., Hammet, F., Mahmoodi, M. S., Pope, B. J., Park, D. J., Mahmood, K., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33024 · Cited by 18
“A limited number of publications have focused on inherited genetic variants that distinguish between risk for aggressive (metastatic) and nonaggressive (low clinical grade) PrCa using a case-case design.(4,21) Here, we report a case-case study of PrCa comparing the prevalence of germline pathogenic genetic variants in…”
MethodSelf-citationSun, X., Ye, D., Du, L., Qian, Y., Jiang, X., & Mao, Y. (2020) · International Journal of Cancer · doi:10.1002/ijc.33221 · Cited by 18
“information of the study design, phenotype definition, quality control and imputation of the genetic data were illustrated previously.(19)”
MethodJung, S. Y., Scott, P. A., Papp, J. C., Sobel, E. M., Pellegrini, M. A., Yu, H., Han, S., & Zhang, Z. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0256 · Cited by 18
“In the secondary QC, we retained SNPs with R̂2 0:6 imputation quality (33).”
Background
Metadata
- Authors
- Study, T. P., Schumacher, F. R., (APCB), A. P. C. B., Study, T. I., Canary PASS Investigators, Breast and Prostate Cancer Cohort Consortium (BPC3), The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, (CAPS), C. O. T. P. I. S., Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS), The Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, Al Olama, A. A., Berndt, S. I., Benlloch, S., Ahmed, M., Saunders, E. J., Dadaev, T., Leongamornlert, D., Anokian, E., Cieza-Borrella, C., Goh, C., Brook, M. N., Sheng, X., Fachal, L., Dennis, J., Tyrer, J., Muir, K., Lophatananon, A., Stevens, V. L., Gapstur, S. M., Carter, B. D., Tangen, C. M., Goodman, P. J., Thompson, I. M., Batra, J., Chambers, S., Moya, L., Clements, J., Horvath, L., Tilley, W., Risbridger, G. P., Gronberg, H., Aly, M., Nordström, T., Pharoah, P., Pashayan, N., Schleutker, J., Tammela, T. L. J., Sipeky, C., Auvinen, A., Albanes, D., Weinstein, S., Wolk, A., Håkansson, N., West, C. M. L., Dunning, A. M., Burnet, N., Mucci, L. A., Giovannucci, E., Andriole, G. L., Cussenot, O., Cancel-Tassin, G., Koutros, S., Beane Freeman, L. E., Sorensen, K. D., Orntoft, T. F., Borre, M., Maehle, L., Grindedal, E. M., Neal, D. E., Donovan, J. L., Hamdy, F. C., Martin, R. M., Travis, R. C., Key, T. J., Hamilton, R. J., Fleshner, N. E., Finelli, A., Ingles, S. A., Stern, M. C., Rosenstein, B. S., Kerns, S. L., Ostrer, H., Lu, Y.-J., Zhang, H.-W., Feng, N., Mao, X., Guo, X., Wang, G., Sun, Z., Giles, G. G., Southey, M. C., MacInnis, R. J., FitzGerald, L. M., Kibel, A. S., Drake, B. F., Vega, A., Gómez-Caamaño, A., Szulkin, R., Eklund, M., Kogevinas, M., Llorca, J., Castaño-Vinyals, G., Penney, K. L., Stampfer, M., Park, J. Y., Sellers, T. A., Lin, H.-Y., Stanford, J. L., Cybulski, C., Wokolorczyk, D., Lubinski, J., Ostrander, E. A., Geybels, M. S., Nordestgaard, B. G., Nielsen, S. F., Weischer, M., Bisbjerg, R., Røder, M. A., Iversen, P., Brenner, H., Cuk, K., Holleczek, B., Maier, C., Luedeke, M., Schnoeller, T., Kim, J., Logothetis, C. J., John, E. M., Teixeira, M. R., Paulo, P., Cardoso, M., Neuhausen, S. L., Steele, L., Ding, Y. C., De Ruyck, K., De Meerleer, G., Ost, P., Razack, A., Lim, J., Teo, S.-H., Lin, D. W., Newcomb, L. F., Lessel, D., Gamulin, M., Kulis, T., Kaneva, R., Usmani, N., Singhal, S., Slavov, C., Mitev, V., Parliament, M., Claessens, F., Joniau, S., Van den Broeck, T., Larkin, S., Townsend, P. A., Aukim-Hastie, C., Gago-Dominguez, M., Castelao, J. E., Martinez, M. E., Roobol, M. J., Jenster, G., van Schaik, R. H. N., Menegaux, F., Truong, T., Koudou, Y. A., Xu, J., Khaw, K.-T., Cannon-Albright, L., Pandha, H., Michael, A., Thibodeau, S. N., McDonnell, S. K., Schaid, D. J., Lindstrom, S., Turman, C., Ma, J., Hunter, D. J., Riboli, E., Siddiq, A., Canzian, F., Kolonel, L. N., Le Marchand, L., Hoover, R. N., Machiela, M. J., Cui, Z., Kraft, P., Amos, C. I., Conti, D. V., Easton, D. F., Wiklund, F., Chanock, S. J., Henderson, B. E., Kote-Jarai, Z., Haiman, C. A., & Eeles, R. A.
- Affiliations
- Case Western Reserve University (US)
- University of Cambridge (GB)
- Division of Cancer Epidemiology and Genetics (US)
- Institute of Cancer Research (GB)
- University of Manchester (GB)
- American Cancer Society (US)
- Griffith University (AU)
- Translational Research Institute (AU)
- Garvan Institute of Medical Research (AU)
- Karolinska University Hospital (SE)
- University of Turku (FI)
- Tampere University (FI)
- Karolinska Institutet (SE)
- Uppsala University (SE)
- Harvard University (US)
- Washington University in St. Louis (US)
- Aarhus University Hospital (DK)
- Oslo University Hospital (NO)
- Aarhus University (DK)
- Princess Margaret Cancer Centre (CA)
- University of Oxford (GB)
- Albert Einstein College of Medicine (US)
- Queen Mary University of London (GB)
- Second Military Medical University (CN)
- Nanjing Medical University (CN)
- Shanghai Medical College of Fudan University (CN)
- Cancer Council Victoria (AU)
- Brigham and Women's Hospital (US)
- The University of Melbourne (AU)
- Monash Health (AU)
- University of Tasmania (AU)
- Universitat Pompeu Fabra (ES)
- Fundación Pública Galega de Medicina Xenómica (ES)
- Universidad de Cantabria (ES)
- Moffitt Cancer Center (US)
- National Institutes of Health (US)
- University of Washington (US)
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- German Cancer Research Center (DE)
- Herlev Hospital (DK)
- The University of Texas MD Anderson Cancer Center (US)
- Cancer Prevention Institute of California (US)
- Universidade do Porto (PT)
- Instituto Português de Oncologia Francisco Gentil (PT)
- Ghent University (BE)
- Ghent University Hospital (BE)
- University of Malaya (MY)
- University Hospital Centre Zagreb (HR)
- University of Alberta (CA)
- Alexandrovska Hospital (BG)
- Southampton General Hospital (GB)
- University of Surrey (GB)
- Universitair Ziekenhuis Leuven (BE)
- Manchester Academic Health Science Centre (GB)
- Inserm (FR)
- Endeavor Health (US)
- Mayo Clinic (US)
- USC Norris Comprehensive Cancer Center (US)
- Dartmouth College (US)
- Royal Marsden NHS Foundation Trust (GB)
- Corresponding author
- Schumacher, Fredrick R.
- Eeles, Rosalind A.
- ORCID
- Schumacher, Fredrick R.
- Berndt, Sonja I.
- Ahmed, Mahbubl
- Saunders, Edward J.
- Dadaev, Tokhir
- Leongamornlert, Daniel
- Anokian, Ezequiel
- Cieza-Borrella, Clara
- Goh, Chee
- Brook, Mark N.
- Sheng, Xin
- Fachal, Laura
- Dennis, Joe
- Tyrer, Jonathan
- Muir, Kenneth
- Lophatananon, Artitaya
- Stevens, Victoria L.
- Gapstur, Susan M.
- Carter, Brian D.
- Tangen, Catherine M.
- Goodman, Phyllis J.
- Thompson, Ian M.
- Batra, Jyotsna
- Chambers, Suzanne
- Moya, Leire
- Clements, Judith
- Horvath, Lisa
- Tilley, Wayne
- Risbridger, Gail P.
- Aly, Markus
- Nordström, Tobias
- Pharoah, Paul
- Pashayan, Nora
- Schleutker, Johanna
- Tammela, Teuvo L. J.
- Sipeky, Csilla
- Auvinen, Anssi
- Albanes, Demetrius
- Weinstein, Stephanie
- Wolk, Alicja
- Håkansson, Niclas
- West, Catharine M. L.
- Dunning, Alison M.
- Burnet, Neil
- Mucci, Lorelei A.
- Giovannucci, Edward
- Andriole, Gerald L.
- Cussenot, Olivier
- Koutros, Stella
- Borre, Michael
- Grindedal, Eli Marie
- Neal, David E.
- Donovan, Jenny L.
- Hamdy, Freddie C.
- Martin, Richard M.
- Travis, Ruth C.
- Hamilton, Robert J.
- Fleshner, Neil E.
- Finelli, Antonio
- Ingles, Sue Ann
- Stern, Mariana C.
- Rosenstein, Barry S.
- Kerns, Sarah L.
- Lu, Yong-Jie
- Zhang, Hong-Wei
- Feng, Ninghan
- Mao, Xueying
- Wang, Guomin
- Giles, Graham G.
- Southey, Melissa C.
- MacInnis, Robert J.
- FitzGerald, Liesel M.
- Kibel, Adam S.
- Drake, Bettina F.
- Vega, Ana
- Szulkin, Robert
- Eklund, Martin
- Kogevinas, Manolis
- Llorca, Javier
- Penney, Kathryn L.
- Stampfer, Meir
- Park, Jong Y.
- Sellers, Thomas A.
- Lin, Hui-Yi
- Stanford, Janet L.
- Cybulski, Cezary
- Ostrander, Elaine A.
- Nordestgaard, Børge G.
- Nielsen, Sune F.
- Weischer, Maren
- Bisbjerg, Rasmus
- Røder, Martin Andreas
- Iversen, Peter
- Brenner, Hermann
- Holleczek, Bernd
- Kim, Jeri
- Logothetis, Christopher J.
- John, Esther M.
- Teixeira, Manuel R.
- Paulo, Paula
- Cardoso, Marta
- Neuhausen, Susan L.
- Steele, Linda
- Ding, Yuan Chun
- Ost, Piet
- Razack, Azad
- Lim, Jasmine
- Teo, Soo-Hwang
- Lin, Daniel W.
- Lessel, Davor
- Gamulin, Marija
- Kaneva, Radka
- Usmani, Nawaid
- Singhal, Sandeep
- Slavov, Chavdar
- Mitev, Vanio
- Parliament, Matthew
- Claessens, Frank
- Joniau, Steven
- Townsend, Paul A.
- Castelao, Jose Esteban
- Roobol, Monique J.
- Jenster, Guido
- van Schaik, Ron H. N.
- Truong, Thérèse
- Xu, Jianfeng
- Khaw, Kay-Tee
- Pandha, Hardev
- Michael, Agnieszka
- Thibodeau, Stephen N.
- McDonnell, Shannon K.
- Schaid, Daniel J.
- Turman, Constance
- Ma, Jing
- Siddiq, Afshan
- Canzian, Federico
- Kolonel, Laurence N.
- Hoover, Robert N.
- Machiela, Mitchell J.
- Cui, Zuxi
- Kraft, Peter
- Amos, Christopher I.
- Conti, David V.
- Easton, Douglas F.
- Wiklund, Fredrik
- Chanock, Stephen J.
- Haiman, Christopher A.
- Eeles, Rosalind A.
- Venue
- Nature Genetics
- Published
- 2018-06-11
- Volume
- 50
- Issue
- 7
- Pages
- 928-936
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC6568012
- OpenAlex
- W2806504012
- Cited by
- 902
- References
- 65
- Citations by year
- 2026: 53 · 2025: 96 · 2024: 133 · 2023: 123 · 2022: 151 · 2021: 132 · 2020: 104 · 2019: 79 · 2018: 30
- FWCI
- 52.93
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-01-08)
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- St George's Online Research Archive (St George's University of London) (acceptedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- Civil War Book Review (submittedVersion)
- eCite Digital Repository (University of Tasmania) (submittedVersion)
- UTAS Research Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HAL (submittedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion)
- Lirias (submittedVersion)
- UTS ePRESS (University of Technology Sydney) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Griffith Research Online (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- U.S. Department of Defense (C5047/A10692, C1287/A10118, C5047/A7357, W81XWH, C1287/A16563, C8197/A16565, C1281/A12014, C5047/A8384, C12292/A11174, C5047/A15007, CA128978, W81XWH1010341, 223175)
- Cancer Research Institute
- Prostate Cancer Foundation
- Breast Cancer Research Foundation (C5047/A10692, C5047/A15007, C1287/A10118, CA128978, 209057, C1287/A16563, W81XWH-10-1-0341, C8197/A16565, C5047/A8384, C1281/A12014, 396414, C12292/A11174, HEALTH-F2-2009-223175)
- Ovarian Cancer Research Fund (W81XWH-10-1-0341, C1281/A12014, C1287/A10118, C8197/A16565, C12292/A11174, CA128978, C5047/A10692, C5047/A15007, C1287/A16563, C5047/A8384, HEALTH-F2-2009-223175)
- University of Southern California (C1281/A12014, C5047/A10692, C8197/A16565, C1287/A10118, C12292/A11174, C5047/A8384, W81XWH-10-1-0341, C5047/A15007, CA128978, C1287/A16563, HEALTH-F2-2009-223175)
- Aarhus Universitet
- Aarhus Universitetshospital
- Case Western Reserve University
- Harvard T.H. Chan School of Public Health
- Institut for Klinisk Medicin, Aarhus Universitet
- National Cancer Research Institute
- Royal Marsden NHS Foundation Trust
- Australian Prostate Cancer Research
- Cancer Research UK (C8197/A16565’, 223175, C1281/A12014, 10119, C5047/A7357, C5047/A15007’, C1287‐A10118, 12014, HEALTHF2-2009-223175, C5047/A3354, 21332, 16561, 16565, C12292/A11174, ‘C5047/A10692, 15007, C1287, C5047/A8384, 10118, 14136, 16563, 18504, 16491, 17528, C16913-A6135, CA128978, A16563, 19169, C1287-A10710, W81XWH-10-1-0341, C1287‐A16563, C1281)
- National Institute for Health and Care Research (C5047/A15007, W81XWH-10-1-0341, NF-SI-0510-10096, C8197/A16565, HEALTH-F2-2009-223175, NF-SI-0509-10242, CA128978, C1287/A10118, C1281/A12014, NF-SI-0512-10114, C5047/A10692, NF-SI-0513-10121, C1287/A16563, C12292/A11174, C5047/A8384)
- University of Cambridge
- University of Warwick
- University College London
- University of Oxford
- European Commission (C1287/A10118, W81XWH-10-1-0341, C1281/A12014, C1287/A16563, C5047/A10692, C5047/A8384, C12292/A11174, C5047/A15007, C8197/A16565, CA128978, 223175)
- University of Bristol
- Prostate Cancer Foundation of Australia
- Monash University
- Griffith University
- Queensland University of Technology
- Cambridge University Hospitals
- Karolinska Institutet (W81XWH-10-1-0341, C1281/A12014, C1287/A10118, HEALTH-F2-2009-223175, C1287/A16563, CA128978, C5047/A8384, C5047/A10692, C12292/A11174, C8197/A16565, C5047/A15007)
- Peter MacCallum Cancer Centre
- Tampereen Yliopisto
- Turun Yliopisto
- Uppsala Universitet
- Tays
- Turun Yliopistollinen Keskussairaala
- National Institutes of Health (C1281/A12014, 223175, W81XWH-10-1-0341, C8197/A16565, C5047/A7357, C12292/A11174, C1287/A16563, W81XWH, C1287/A10118, HHSN268201200008I, C5047/A10692, HEALTH-F2-2009-223175, C5047/A15007, C5047/A8384, X01HG007492)
- Canadian Institutes of Health Research (C5047/A8384, C5047/A15007, C5047/A10692, C1287/A10118, C1287/A16563, CA128978, C8197/A16565, C1281/A12014, C12292/A11174, W81XWH-10-1-0341, HEALTH-F2-2009-223175, 223175)
- Medical Research Council (C12292/A11174, C1281/A12014, CA128978, C5047/A8384, HEALTH-F2-2009-223175, C8197/A16565, W81XWH-10-1-0341, C1287/A16563, C5047/A10692, MR/N003284/1, C1287/A10118, C5047/A15007)
- National Health and Medical Research Council (623204, 504702, 126402, 614296, 251533, 504700, 504715)
- Cancer Council Victoria (C1287/A16563, C1287/A10118, C8197/A16565, HEALTH-F2-2009-223175, C1281/A12014, C5047/A15007, C12292/A11174, W81XWH-10-1-0341, CA128978, C5047/A10692, C5047/A8384)
- Cancer Council Queensland
- Warwick Medical School
- Servicio Gallego de Salud
- Monash Biomedicine Discovery Institute, Monash University
- National Heart, Lung, and Blood Institute (HHSN268201200008I, HHSN268201200008C)
- National Cancer Institute (R01CA128978, U01CA188392, C5047/A15007, C5047/A10692, C5047/A8384, U19CA148065, HEALTH-F2-2009-223175, W81XWH-10-1-0341, UM1CA182883, UG1CA189974, U01CA098710, U19CA148537, K05CA175147, CA148065, U01CA098216, C1281/A12014, C12292/A11174, U01CA098758, U19CA148112, (CA128978, C1287/A16563, K07CA187546, C1287/A10118, C8197/A16565, U01CA098233, U10CA037429)
- Division of Cancer Epidemiology and Genetics, National Cancer Institute
- DOD Prostate Cancer Research Program
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- prostate cancer, cancer susceptibility loci, genetic association, early-onset prostate cancer, polygenic risk score, ATM, p27, European ancestry, risk prediction, fine mapping
- MeSH terms
- Genotype, Humans, Male, Prostatic Neoplasms, Risk, Case-Control Studies, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Genome-Wide Association Study, Genetic Loci
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
